Abstract
The absorption of flucytosine from the digestive tract is very good but minimal with amphotericin B. For this reason, amphotericin B has to be injected intravenously. Fungistatic levels are achieved rapidly with flucytosine and slowly with amphotericin B, since the dose has to be increased slowly. Distribution of flucytosine in other body fluids is high, whereas with amphotericin B it is poor. Flucytosine is excreted mainly via the kidney without metabolism, whereas amphotericin B is eliminated mainly by metabolism. Therefore, amphotericin B dosage does not have to be adapted to kidney function, which is the case for flucytosine. The half-life of flucytosine is short (hours), that of amphotericin B is long (days); flucytosine is haemodialysable, whereas amphotericin B, probably owing to the high protein binding, is not.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Atkinson A. J., Jr, Bennett J. E. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother. 1978 Feb;13(2):271–276. doi: 10.1128/aac.13.2.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Atkinson A. J., Jr, Bindschadler D. D. Pharmacokinetics of intrathecally administered amphotericin B. Am Rev Respir Dis. 1969 Jun;99(6):917–924. doi: 10.1164/arrd.1969.99.6.917. [DOI] [PubMed] [Google Scholar]
- Bindschadler D. D., Bennett J. E. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis. 1969 Oct;120(4):427–436. doi: 10.1093/infdis/120.4.427. [DOI] [PubMed] [Google Scholar]
- Dawborn J. K., Page M. D., Schiavone D. J. Use of 5-fluorocytosine in patients with impaired renal function. Br Med J. 1973 Nov 17;4(5889):382–384. doi: 10.1136/bmj.4.5889.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Drouhet E., Babinet P., Chapusot J. P., Kleinknecht D. 5-Fluorocytosine in the treatment of candidiasis with acute renal insufficiency: its kinetics during haemodialysis and peritoneal dialysis. Biomedicine. 1973 Sep 20;19(9):408–414. [PubMed] [Google Scholar]
- Dufresne J. J. Le traitement de la méningo-encéphalite cryptococcique; intérêt de la 5-fluorocytosine. Rev Med Suisse Romande. 1972 Aug;92(8):597–614. [PubMed] [Google Scholar]
- Fields B. T., Jr, Bates J. H., Abernathy R. S. Amphotericin B serum concentrations during therapy. Appl Microbiol. 1970 Jun;19(6):955–959. doi: 10.1128/am.19.6.955-959.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jagdis F. A., Hoeprich P. D., Lawrence R. M., Schaffner C. P. Comparative pharmacology of amphotericin B and amphotericin B methyl ester in the non-human primate, Macacca mulatta. Antimicrob Agents Chemother. 1977 Nov;12(5):582–590. doi: 10.1128/aac.12.5.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kauffman C. A., Frame P. T. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother. 1977 Feb;11(2):244–247. doi: 10.1128/aac.11.2.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Normark S., Schönebeck J. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata. Antimicrob Agents Chemother. 1972 Sep;2(3):114–121. doi: 10.1128/aac.2.3.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schönebeck J., Polak A., Fernex M., Scholer H. J. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy. 1973;18(6):321–336. doi: 10.1159/000221279. [DOI] [PubMed] [Google Scholar]
- Wade D. N., Sudlow G. The kinetics of 5-fluorocytosine elimination in man. Aust N Z J Med. 1972 May;2(2):153–158. doi: 10.1111/j.1445-5994.1972.tb03925.x. [DOI] [PubMed] [Google Scholar]